cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vanda Pharmaceuticals Inc
8 own
15 watching
Current Price
$0
$0.02
(0.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
373.37M
52-Week High
52-Week High
11.9
52-Week Low
52-Week Low
5.75
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
29.8155
iconMarket Capitalization373.37M
icon52-Week High11.9
icon52-Week Low5.75
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio29.8155
What does the Vanda Pharmaceuticals Inc do?
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Read More
How much money does Vanda Pharmaceuticals Inc make?
News & Events about Vanda Pharmaceuticals Inc.
PR Newswire
1month ago
Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information PR Newswire WASHINGTON, May 2, 2023 WASHINGTON, May 2, 2023 /PRNewswire...
PR Newswire
2 months ago
Vanda Prevails in Jet Lag Litigation Against the FDA Vanda Prevails in Jet Lag Litigation Against the FDA PR Newswire WASHINGTON, March 28, 2023 WASHINGTON, March 28, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced a win in its jet lag FOIA litigation against...
PR Newswire
2 months ago
Vanda Pharmaceuticals Appoints Dr. Tage Honor to its Board of Directors Vanda Pharmaceuticals Appoints Dr. Tage Honor to its Board of Directors PR Newswire WASHINGTON, March 17, 2023 WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the...
Benzinga
4 months ago
read more...
PR Newswire
5 months ago
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference PR Newswire WASHINGTON, Jan. 6, 2023 WASHINGTON, Jan. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq...
Frequently Asked Questions
Frequently Asked Questions
What is Vanda Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Vanda Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Vanda Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Vanda Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Vanda Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Vanda Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Vanda Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Vanda Pharmaceuticals Inc?
plus_minus_icon
What percentage is Vanda Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Vanda Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.02
(0.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$21.63
$-0.32 (-1.44 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$7.06
$0.11 (1.51 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$13.77
$-0.09 (-0.65 %)
Omeros Corporation
Omeros Corporation
$7.54
$-0.03 (-0.40 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$21.63
$-0.32 (-1.44 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$7.06
$0.11 (1.51 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$13.77
$-0.09 (-0.65 %)
Omeros Corporation
Omeros Corporation
$7.54
$-0.03 (-0.40 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00